A chemical probe to modulate human GID4 Pro/N-degron interactions.
Dominic D G OwensMatthew E R MaitlandAliakbar Khalili YazdiXiaosheng SongViviane ReberMartin Peter SchwalmRaquel Arminda Carvalho MachadoNicolas BauerXu WangMagdalena M SzewczykCheng DongAiping DongPeter LoppnauMatthew F CalabreseMatthew S DowlingJisun LeeJustin I MontgomeryThomas N O'ConnellChakrapani SubramanyamFeng WangElla C AdamsonMatthieu SchapiraMatthias GstaigerStefan KnappMasoud VedadiJinrong MinGilles A LajoieDalia Barsyte-LovejoyDafydd R OwenCaroline Schild-PoulterCheryl H ArrowsmithPublished in: Nature chemical biology (2024)
The C-terminal to LisH (CTLH) complex is a ubiquitin ligase complex that recognizes substrates with Pro/N-degrons via its substrate receptor Glucose-Induced Degradation 4 (GID4), but its function and substrates in humans remain unclear. Here, we report PFI-7, a potent, selective and cell-active chemical probe that antagonizes Pro/N-degron binding to human GID4. Use of PFI-7 in proximity-dependent biotinylation and quantitative proteomics enabled the identification of GID4 interactors and GID4-regulated proteins. GID4 interactors are enriched for nucleolar proteins, including the Pro/N-degron-containing RNA helicases DDX21 and DDX50. We also identified a distinct subset of proteins whose cellular levels are regulated by GID4 including HMGCS1, a Pro/N-degron-containing metabolic enzyme. These data reveal human GID4 Pro/N-degron targets regulated through a combination of degradative and nondegradative functions. Going forward, PFI-7 will be a valuable research tool for investigating CTLH complex biology and facilitating development of targeted protein degradation strategies that highjack CTLH E3 ligase activity.
Keyphrases
- anti inflammatory
- endothelial cells
- induced pluripotent stem cells
- pluripotent stem cells
- high glucose
- single cell
- transcription factor
- type diabetes
- high resolution
- mass spectrometry
- stem cells
- blood pressure
- metabolic syndrome
- small molecule
- living cells
- skeletal muscle
- mesenchymal stem cells
- electronic health record
- quantum dots
- artificial intelligence
- drug induced
- cancer therapy